#Roche presented its late stage pipeline today at #JPM20, with #tecentriq heading up #oncology with six anticipated indications, includin...

A next generation CD-19 mAb, tafasitamab is all the buzz at #JPM2020! #Incyte acquired tafasitamab from #Morphosys, who had been developi...

#JPM2020 is right around the corner! The #Kognitic team is excited to hear from numerous industry leaders what is next for the pharma ind...

The American Cancer Society has released the cancer facts and figures for 2019. With almost 17 million Americans living with a history of...

Kognitic is excited to be heading to #JPM2020 to discuss the latest in innovative strategy for the pharma industry! Check out our website...

Thank you Healthcare Tech Outlook for featuring Kognitic in the Top Ten Oncology Companies of 2019. We are thrilled to be listed alongsid...

A recent study has found that antibodies which target PD-L1 are more effective than PD-1 inhibitors at blocking PD-1/PD-L1 signaling (see...

We would like to celebrate Amgen’s partnership with the Lazarex Cancer Foundation, an organization which is dedicated to creating equitab...

In honor of Lung Cancer Awareness Day (August 1st), we would like to call attention to assets currently in phase III for small cell lung ...

Eli Lilly announced that it is pulling the plug on LY3415244, the company’s only bispecific antibody currently in pipeline (see attached ...

Interesting article about BMS expanding Opdivo's colorectal cancer indication. Which companies could be impacted by this expansion? Kogni...

The number of emerging transformative therapy clinical trials are on the rise for the past few years. The therapies target multiple tumor...

Number of industry sponsored clinical trials in immunotherapy over the past two years. Classification of Immunotherapy and the tumors the...

Automation and new computer technologies are revolutionizing all industrial areas. Until a few years ago, developing a new product was ex...